Integrative Cancer Centers of America
Our team of caring and experienced cancer doctors believes in providing the patient with a very individualized and personal treatment program, including unique and innovative treatments. The treatment of cancer is an ever-growing field. Our clinical and medical researchers are on the cutting edge of innovation, researching new natural, non-toxic treatment modalities to bring you the very best possible care without compromising your quality of life.
Integrative Cancer Centers of America
And unlike many traditional or what we term conventional "standard of medicine" cancer clinics, our doctors offer more than the big three: chemotherapy, radiation and/or surgery.
Our Philosophy is simple; Restore Hope and Restore Life to our patients. Our Centers employ therapies that effectively treat the cancer tumors cells without compromising the patient's quality of life in the process.
Advisors & Clinicians
Gregory DiRienzo, CEO
Founder and Chief Executive Officer of Integrative Cancer Centers America, founder and current CEO of ProGenaCell, Inc. (progenacell.com), an international stem cell healthcare provider, founder and former CEO of New Life Cancer Centers, Inc.; founder and CEO of Medici Integrative Health & Surgery Center (medicicenterintegrativehealth.com); founder and former CEO of New Cell Sciences, a biomedical research and development company, former CEO of PDA Solutions, an innovative medical software company; former Managing Partner of Bailey, Charles & Gregory, a civil and criminal litigation consulting firm; former institutional banker; B.Sc. San Diego State University; post-graduate studies in international finance and banking.
Salvador Vargas, M.D.
Board Certified Oncologist. Dr. Vargas is a licensed physician with 34 years of experience in Chronic Disease, Cancer, Alternative and Conventional treatments. Graduate school of Medicine,Universidad Autonoma de Puebla, Mexico; Internship, Hospital Del Mar, Baja California; Internist, Hospital International, Puebla, Mexico, Center for Oncology & Treatment; Academic Medical Proficiency and Certification by Educational Commission for Foreign Medical Graduates and Federal Licensing Examination accreditation by the Board of Medical Quality Assurance California, U.S.; Trained adjuvant for combined therapies in cancer 1986; Certification xeno-transplant therapeutics for diverse nonmalignant degenerative diseases; Immune-enhancing adjuvancy in cancer therapy; Integrative medicine in cancer Chemo-Radiation synergy protocols & pre-surgical cytoreduction protocols; hormone therapy; conservative cytostatic modified programs; adjuvant non-traditional modalities including immuno-enhancing cancer; development of integrative and modified treatments in oncology at Services de Oncology Medical Integral, B.C.; Member medical advisory board at G SAM Hospital, an innovative integrative cancer treatment group in Gunpo/Seoul, South Korea.
Heberto Schramm, MD
Licensed Surgeon, Stem Cell Clinician, and Researcher; Graduate School of Medicine, Universidad Autónoma de Baja California, Baja California. Dr. Schramm is a licensed physician and twenty-three-year practicing surgeon with emphasis in Oncology and reconstructive surgery. Dr. Schramm is also a trained researcher in Genetics with a particular focus in Cancer Research and Clinical Efficacy, as well as a Clinician and International lecturer on Allo, Autologus, and Xeno Cell transplantation.
Ricardo Ramos, MD
Ulises Nieves, MD
Licensed Anesthesiologist and Pain Management Specialist. Graduate School Universidad Autonoma de Baja California.
Michel Baudry, PhD
Dean, Graduate College of Biomedical Sciences at Western University of Health Sciences; former professor of biological sciences, neurology and biomedical engineering at University of Southern California; internationally known neuroscientist who has published more than 400 manuscripts in peer-reviewed journals; one of the 100 most-cited neuroscientists in the world, according to the ISI database; served on numerous National Science Foundation and National Institutes of Health panels; graduated from Ecole Polytechnique, Paris in 1971; earned PhD in biochemistry at University of Paris VII in 1977 under direction of professors J.C. Schwartz and J.P. Changeux, two of France's most distinguished neurobiologists.
Xiaoning Bi, MD, PhD
Professor of Physiology, College of Osteopathic Medicine of Pacific, Western University of Health Sciences; Ph.D., Neurobiology, Neuroscience Program, University of Southern California, Los Angeles, CA, 1996, M.D., Neuroanatomy, Brain Research Institute, Zurich University, Switzerland, 1994, M.S., Neurophysiology, Third Military Medical University, P.R. China, 1986, M.D., Medicine, Binzhou Medical University, P.R. China, 1982, Postdoctoral Fellow, Dept. of Anatomy and Neurobiology, UCI, Irvine, CA, 1997-1998 & Postdoctoral Fellow, Neuroscience, USC 1996-1997.
Sergey L. Znoyko, MD, PhD
Clinician, Researcher, received MD from Moscow Medical Institute in 1981; finished residency in Endocrinology at Moscow Medical Institute and City Hospital No. 52; in 1996 received PhD in Developmental Biology from Russian Academy of Sciences; from 2003 to 2004 postdoctoral fellow in Cellular Biology and Anatomy at the Medical University of South Carolina; from 1999 to 2003 postdoctoral fellow in Ophthalmology at Storm Eye Institute, Medical University of South Carolina.
Dr. Juan Raul Gil Frias, MD
30-year Licensed Surgeon, Doctor of Cancer Vaccines, Bio-medicines; Bio-technology; Graduate School UNAM; held chief posts as physician, surgeon at IMSS National Medical Center; University of Guadalajara, Diploma Alternative Medicine, Clinical Psychology; Diploma University of Havana, Regenerative Medicine & Molecular and Alternative Medicine. Served as Surgeon in Charge and Department Head Emergency Hospital Guadalajara 13 years.
Dr. Carlos Cortez Garcia, MD
Licensed Critical Care Oncologist and Internist. Graduate School Universidad Autonoma de Baja California.
Intra-tumoral Immunotherapy ™
Integrative Cancer Centers America introduces Intra-tumoral Immunotherapy ™ a precision tumor-targeted immuno-modulating therapy for treatment of advanced solid tumor cancers, always with minimal, or no side effects.